Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission (rebond-jas)

October 1, 2026 updated by: Institut Paoli-Calmettes

REBOND JAS: Feasibility Study of a Sport-Inspired Onco-Coaching Program for Young Adults in Cancer Remission: Rebond-JAs-IPC 2025-017

This is a single-center, non-randomized feasibility study. For this study, 19 young adults treated for cancer at the Paoli-Calmettes Institute will be included.This study includes interviews and questionnaires to assess the adherence rate. It will be measured by the percentage of patients who attend the first two coaching sessions (either in person or via videoconference) relative to the total number of patients included in the study.

The invitation to participate in this program will be made by the surgeon, hematologist, oncologist, or radiation therapist.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The first coaching session must take place within one month following inclusion. Coaching sessions will involve all patients enrolled in the study.

Coaching sessions with the coach will be offered as monthly individual interviews over a period ranging from 2 to 6 months. The frequency of sessions will be co-determined by the coach and the participant, depending on the participant's needs. The coach will aim to schedule sessions with at least one month between them. Therefore, patients will have a minimum of 2 and a maximum of 6 onco-coaching sessions.

Sessions will be held at the Faculty of Sports Sciences, in a dedicated office. The first session must be conducted in person. Subsequent sessions may be conducted remotely (by phone or videoconference), depending on patient preferences. This option is supported by findings from recent studies (McCann et al., 2019; Mostafa et al., 2025; Zhong et al., 2025).

During sessions, the coach uses standard motivational interviewing techniques (Miller, 1983). Through the use of open-ended questions, active and reflective listening, positive reinforcement and validation techniques, as well as regular reformulation of what is expressed, the coach reveals contradictions and ambivalence, defuses resistance, and promotes self-determined strategies for change (Miller and Rollnick, 2002).

From the first session, the coach works with each participant to define personalized goals and a strategy to achieve them, including identifying available resources. Each session should last between 45 minutes and 1 hour.Questionnaires:

QEEC-AYAs: A tool designed to measure the psychosocial needs of adolescents and young adults during and after treatment. Developed by Justafré et al. (2023), it includes 48 items divided into 7 dimensions: information (8 items), care team (6 items), physical health (4 items), emotional health (14 items), sexual and reproductive health (6 items), health behaviors and well-being (4 items), and daily life (6 items). The questionnaire demonstrates strong psychometric properties, with Cronbach's alpha values above 0.80.

Interviews:

These semi-structured interviews will be conducted to analyze the impact of the intervention on patients and to better understand the underlying processes. They will be carried out by researchers specialized in social psychology and quantitative data analysis, using a semi-structured adaptive interview guide. Each interview will last between 30 minutes and 1 hour.

The first semi-structured interview will be conducted in a room at the Faculty of Sports Sciences by at least two researchers. The second interview may be conducted either remotely or in person at the Faculty of Sports Sciences.

All interviews must be recorded using a voice recorder, then pseudonymized (only the study ID number) and transferred to the secure server of the Management Sport Cancer laboratory. The recordings must then be deleted from the voice recorder.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
19

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Male or female aged 18 to 25 at the time of cancer diagnosis and/or at the time of inclusion.In complete remission, within one year following the end of treatment and at the time of inclusion

Description

Inclusion Criteria:

  • Male or female aged 18 to 25 at the time of cancer diagnosis and/or at the time of inclusion.
  • In complete remission, within one year following the end of treatment and at the time of inclusion.
  • Treated at the Comprehensive Cancer Center Institut Paoli-Calmettes.
  • Able to speak and write in French.
  • Has not objected to participation in the study.
  • Affiliated with a social security scheme or beneficiary of such a scheme.

Non -Inclusion Criteria:

  • Patient undergoing treatment, except for maintenance therapy.
  • Patient experiencing a relapse.
  • Person in an emergency situation, legally protected adult (under guardianship, curatorship, or judicial protection), or unable to express non-opposition.
  • Patient with clinically confirmed psychological symptoms (e.g., receiving antidepressants, mood stabilizers, anxiolytics, etc.).
  • Inability to comply with study follow-up due to geographic, social, or psychological reasons.

Exclusion Criteria:

Relapse occurring between inclusion and the second onco-coaching session.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The primary objective of the study is to assess the feasibility of a sport-inspired onco-coaching program by evaluating the participation rate of young adults in the first two coaching sessions.
Time Frame: 2 years

The primary evaluation criterion of the study will be the adherence rate to the onco-coaching program.

It will be measured by the percentage of patients who attend the first two coaching sessions (either in person or via videoconference) relative to the total number of patients enrolled in the study.

The invitation to participate in the program will be made by the surgeon, hematologist, oncologist, or radiation therapist.
2 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
To identify the success and failure factors of the extrahospital support program through qualitative interviews.
Time Frame: 2 years

Assessment of participants' satisfaction with the program through semi-structured interviews
2 years
To evaluate overall adherence to the onco-coaching program
Time Frame: 2 years

Compliance with the onco-coaching program, measured empirically across all scheduled visits by assigning equal weight to all participants, regardless of the number of visits planned.
2 years
To collect and characterize the reasons why patients decline to participate in the study
Time Frame: 2 years

Number of refusals to sign the informed consent form.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Institut Paoli-Calmettes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 3, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 3, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 3, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Rebond-JAs-IPC 2025-017

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings